Przegląd doniesień na temat wpływu melatoniny na patogenezę i terapię raka piersi
 
Więcej
Ukryj
1
Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach
 
 
Autor do korespondencji
Kinga Grabińska   

Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w KatowicachKatowice, ul. Ligocka 5/16, tel. +48 694 159 122, +48 505 597 250
 
 
Ann. Acad. Med. Siles. 2010;64:58-70
 
SŁOWA KLUCZOWE
STRESZCZENIE
Melatonina pełni przede wszystkim funkcję biochemicznego regulatora rytmów okołodobowych i sezonowych, ale szczególne zainteresowanie naukowców wzbudzają udowodnione już jej właściwości antyoksydacyjne i immunomodulujące oraz jej wpływ na regulację wydzielania innych hormonów. W ostatnich latach zostało przeprowadzonych wiele badań dotyczących roli oraz potencjalnego zastosowania melatoniny w profi laktyce i leczeniu różnych jednostek chorobowych. Praca jest przeglądem piśmiennictwa dotyczącego badań nad wpływem melatoniny na patogenezę raka sutka i jej terapeutycznego zastosowania w tym nowotworze. Badano prawdopodobne mechanizmy onkostatyczne dotyczące wpływu na oś podwzgórzowo-przysadkowo-gonadalną oraz działanie melatoniny jako selektywnego modulatora receptora estrogenowego (SERM) i enzymów biorących udział w biosyntezie estrogenów w tkankach obwodowych (SEEM). Ponadto zaobserwowano związek między zaburzeniami rytmu dobowego u kobiet a wzrostem ryzyka zachorowania na raka sutka. Celem niniejszej pracy jest przedstawienie mechanizmów działania melatoniny i jej zastosowania w onkologii.
ISSN 0208-5607
 
REFERENCJE (72)
1.
Zawilska J.B., Nowak J.Z. Rytmika okołodobowa i zegar biologiczny. Sen. 2002; 2(4): 127–136.
 
2.
Arendt J. Melatonin and the pineal gland: infl uence on mammalian seasonal and circadian physiology. Reviews of Reproduction. 1998; 3: 13-22.
 
3.
Zawilska J.B., Nowak J.Z. Melatonin: from biochemistry to therapeutic applications. Pol. J. Pharmacol. 1999; 51: 3–23.
 
4.
Zawilska J.B., Nowak J.Z. Regulatory mechanisms in melatonin biosynthesis in retina. Neurochem. Int. 1992; 20: 23–36.
 
5.
Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991; 12: 151–180.
 
6.
Nowak J.Z., Zawilska J.B. Melatonina jako koordynator rytmów biologicznych: regulacja biosyntezy, działania fi - zjologiczne i znaczenie terapeutyczne. Lęk i Depresja. 1996; 1: 189-211.
 
7.
Reiter R.J. Melatonin: the chemical expression of darkness. Mol. Cell. Endocrinol. 1991; 79: C153–C158.
 
8.
Stevens R.G. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int. J. Epidemiol. 2009; 38(4): 963-970.
 
9.
Lewczuk B. Siatkówka, jądro skrzyżowania oraz szyszynka jako elementy zegara biologicznego ssaków. Medycyna Wet. 2007; 63(5): 506-511.
 
10.
Hannibal J. Neurotransmitters of the retino-hypothalamic tract. Cell Tissue Res. 2002; 309: 73-88.
 
11.
Hannibal J., Ding J.M., Chen D., Fahrenkrug J., Larsen P.J., Gillette M.U., Mikkelsen J.D. Pituitary adenylate cyclase-activating peptide (PACAP) in the retinohypothalamic tract: a potential daytime regulator of the biological clock. J. Neurosci. 1997; 17: 2637-2644.
 
12.
Moore R.Y., Speh J.C., Leak R.K. Suprachiasmatic nucleus organization. Cell Tissue Res. 2002; 309: 89-98.
 
13.
Danielczyk K., Dziegiel P. MT1 melatonin receptors and their role in the oncostatic action of melatonin. Postępy Hig Med Dosw (Online). 2009; 63: 425-434.
 
14.
Cos S., González A., Martínez-Campa C., Mediavilla M.D, Alonso-González C., Sánchez-Barceló E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detection and Prevention. 2006; 30: 118-128.
 
15.
Blask D.E., Sauer L.A., Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002; 2(2): 113-132.
 
16.
Reiter R.J., Tan D.X., Terron M.P., Flores L.J., Czarnocki Z. Melatonin and its metabolites: new fi ndings regarding their production and their radical scavenging actions. Acta Biochim Pol. 2007; 54(1): 1-9.
 
17.
Karasek M. Szyszynka i melatonina. Wydawnictwo Naukowe PWN, Warszawa –Łódź 1997.
 
18.
Dziegiel P., Podhorska-Okołów M., Zabel M. Melatonin: adjuvant therapy of malignant tumors. Med Sci Monit. 2008; 14(5): RA64-70.
 
19.
Girgert R., Hanf V., Emons G., Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. 2009; 47: 23-31.
 
20.
Hill S.M., Frasch T., Xiang S., Yuan L., Duplessis T., Mao L. Molecular mechanisms of melatonin anticancer eff ects. Integr Cancer Ther. 2009; 8(4): 337-346.
 
21.
Solár P. Melatonin and its wide-spectrum eff ects: use of melatonin in the treatment of tumors. Cesk Fysiol. 1999; 48(1): 27-40.
 
22.
Moss R.W. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther. 2007; 6(3): 281-292.
 
23.
Bilski B. Czy praca zmianowa jest czynnikiem ryzyka choroby nowotworowej? Medycyna Pracy. 2005; 56(2): 175-178.
 
24.
Rögelsperger O., Ekmekcioglu C., Jäger W. i wsp. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009; 46(4): 422-432.
 
25.
Cucina A., Proietti S., D’Anselmi F., Coluccia P., Dinicola S., Frati L., Bizzarri M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res. 2009; 46(2): 172-180.
 
26.
Dillon D.C., Easley S.E., Asch B.B. i wsp. Diff erential expression of high-affi nity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002; 118(3): 451-8.
 
27.
Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Sánchez-Barceló E.J. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008; 8: 691-702.
 
28.
Mediavilla M.D., Cos S., Sánchez- Barceló E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999; 65(4): 415-420.
 
29.
Blask D.E. Melatonin, sleep disturbance and cancer risk, 2008; 13: 257-264.
 
30.
Blask D.E., Dauchy R.T., Brainard G.C., Hanifi n J.P. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther. 2009; 8(4): 347-353.
 
31.
Srinivasan V., Spence D.W., Pandi-Perumal S.R., Trakht I., Cardinali D.P. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008; 7(3): 189-203.
 
32.
Jassem J., Bobek-Biliewicz B., Krzakowski M. i wsp. Rak Piersi. Krzakowski M., Herman K., Jassem J. i wsp. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – 2009. Część I. Via Medica, Gdańsk 2009: 185- 231.
 
33.
Feigelson H.S., Henderson B.E. Estrogens and breast cancer. Carcinogenesis. 1996; 17: 2279-2284.
 
34.
Russo I.H., Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998; 3: 49–61.
 
35.
Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985; 45: 2900–2906.
 
36.
Yue W., Wang J.P., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998;58:927–32.
 
37.
Yue W., Santen R.J., Wang J.P. i wsp. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003; 86: 477–486.
 
38.
Wong Z.W., Ellis M.J. First-line endocrine treatment of breast cancer: aromatase inhibitor or antiestrogen? Br J Cancer. 2004; 90: 20–25.
 
39.
Molis T.M., Spriggs L.L., Hill S.M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 1994; 8: 1681–1690.
 
40.
Molis T.M., Walters M.R., Hill S.M. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cancer cells. Int J Oncol. 1993; 3: 687–694.
 
41.
Rato A.G., Pedrero J.G., Martinez M.A., del Rio B., Lazo P.S., Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999; 13: 857–868.
 
42.
Aronika S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signalling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA. 1994; 91: 8517–8521.
 
43.
Kiefer T., Ram P.T., Yuan L., Hill S.M. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat. 2002; 71: 37–45.
 
44.
Dai J., Inscho E.W., Yuan L., Hill S.M. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res. 2002; 32: 112–9.
 
45.
Del Rio B., Garcı´a-Pedrero J.M., Martı´nez-Campa C., Zuazua P., Lazo P.S., Ramos S. Melatonin: an endogenous specifi c inhibitor of estrogen receptor a via calmodulin. J Biol Chem. 2004;.279: 38294–38302.
 
46.
Cos S., Martı´nez-Campa C., Mediavilla M.D., Sa¨nchez-Barcelo´ E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005; 38: 136–142.
 
47.
Reiter R.J., Tan D.X., Erren T.C., Fuentes- Broto L., Paredes S.D. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther. 2009; 8(4): 337-46.
 
48.
Oh E.Y., Ansell C., Nawaz H., Yang C.H., Wood P.A., Hrushesky W.J. Global breast cancer seasonality. Breast Cancer Res Treat. 2010; 123(1): 233-243.
 
49.
Cohen M., Lippman M., Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978; 2(8094): 814-816.
 
50.
Davis S., Mirick D.K. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control. 2006; 17(4): 539-545.
 
51.
Chen S.T., Choo K.B., Hou M.F., Yeh K.T., Kuo S.J., Chang J.G. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26(7): 1241-6.
 
52.
Schernhammer E.S., Hankinson S.E. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009; 18(1): 74-79.
 
53.
Nagata C., Nagao Y., Yamamoto S., Shibuya C., Kashiki Y., Shimizu H. Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. Cancer Epidemiol Biomarkers Prev. 2008; 17(6): 1418-1423.
 
54.
Schernhammer E.S., Berrino F., Krogh V. i wsp. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008; 100(12): 898-905.
 
55.
Kloog I., Haim A., Stevens R.G., Barchana M., Portnov B.A. Light at night codistributeswith incident breast but not lung cancer in the female population of Israel. Chronobiol Intl. 2008; 25: 65–81.
 
56.
Stevens R.G. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987; 125(4): 556-561.
 
57.
Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006; 17(4): 531-537.
 
58.
Davis S., Mieick D.K., Stevens G. Night shift work, Light at night, and risk of breast cancer. J Natl Cancer Inst. 2001; 93(20): 1557-1562.
 
59.
Schernhammer E.S., Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004; 90(5): 941–943.
 
60.
Hahn R.A. Profound bilateral blindness and the incidence of breast cancer. Epidemiology. 1991; 2(3): 208-210.
 
61.
Pukkala E., Verkasalo P.K., Ojamo M., Rudanko S.L. Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control. 1999; 10(1): 13-20.
 
62.
Feychting M., Osterlund B., Ahlbom A. Reduced cancer incidence among the blind. Epidemiology. 1998; 9(5): 490-494.
 
63.
Flynn-Evans E.E., Stevens R.G., Tabandeh H., Schernhammer E.S., Lockley S.W. Total visual blindness is protective against breast cancer. Cancer Causes Control. 2009; 20(9): 1753-1756.
 
64.
Verkasalo P.K., Lillberg K., Stevens R.G. Sleep Duration and Breast Cancer: A Prospective Cohort Study. Cancer Res. 2005; 65: 9595-9600.
 
65.
Wu A.H., Wang R., Koh W.P., Stanczyk F.Z., Lee H.P., Yu M.C. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis. 2008; 29: 1244-1248.
 
66.
Kakizaki M., Kuriyama S., Sone T. i wsp. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer. 2008; 99(9): 1502-1505.
 
67.
Erren T.C., Piekarski C. Does winter darkness in the Arctic protect against cancer? The melatonin hypothesis revisited. Med Hypotheses. 1999; 53: 1–5.
 
68.
Davis S., Kaune W.T., Mirick D.K., Chen C., Stevens R.G. Residential magnetic fi elds, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol. 2001; 154(7): 591-600.
 
69.
Girgert R., Hanf V., Emons G., Gründker C. Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fi elds. Bioelectromgnetics. 2010; 31(3): 237-245.
 
70.
Chen C., Ma X., Zhong M., Yu Z. Extremely low-frequency electromagnetic fi elds exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls. Breast Cancer Res Treat. 2010; 123(2): 569-576.
 
71.
Kolstad H.A. Nightshift work and risk of breast cancer and other cancers--a critical review of the epidemiologic evidence. Scand J Work Environ Health. 2008; 34(1): 5-22.
 
72.
Travis R.C., Allen D.S., Fentiman I.S., Key T.J. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004; 96(6): 475-482.
 
eISSN:1734-025X
Journals System - logo
Scroll to top